Gilles Salles

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Gilles Salle
Nationality French
Alma mater Claude Bernard University Lyon 1
Scientific career
Fields Hematology Lymphoma
Institutions South Lyon Hospital Complex, Lyon, France

Gilles Salles is a French University Professor, Medical Doctor and a specialist in haematological oncology, notably lymphomas. He is one of the most cited European scientists in the areas of haematology and lymphoma.[1]

Salles is the head of the Steering Committee of the CALYM consortium.

Career[edit]

He has obtained his master DEA degree in Differentiation, Genetics and Immunology from the Claude Bernard University of Lyon in 1986. In 1989 he continued his university studies and graduated as a Doctor of Medicine, in 1992 he obtained an Advanced Specialised Studies Degree in Cancerology. 1994 he defended his thesis in immunology on the Signals that regulate the formation of B lymphocytes. He has completed his post-doctorate fellowship at the Dana Farber Cancer Institute of the Harvard Medical School of Boston in the United States.[2]

Since 1996, he is the head of the research team “Indolent B-cell proliferation” currently affiliated with the Laboratoire de Biologie Moléculaire de la Cellule (UMR5239 : ENS-Lyon, CNRS, Université Claude Bernard, Hospices Civils de Lyon), that examines several aspects of lymphoma biology (senescence and apoptosis in lymphocytes, biology of splenic marginal zone, prognostic factors in lymphoma).

Previous he also held the Chair of the Leukaemia Committee of the “Fondation de France” (2005–07) and the Chair of the Scientific Programme Committee of the European Hematology Association (EHA) for its 13th Congress (2008).

At the moment Gilles Salles holds the following positions:[citation needed] - Professor of Medicine (Haematology) at Université Lyon-1, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux (1996) - Chair of the Clinical Haematology Department at the Hospices Civils de Lyon (Centre Hospitalier Lyon-Sud) (2011) - Chair of the research team “Indolent B-cell proliferation” in the LBMC - UMR 5239 (ENS - CNRS – UCB - HCL) (2007) - Chair of the LYSA cooperative group (leading cooperative group in lymphoma research) (2012) - Vice-president in charge of research at the board of Directors of the Hospices Civils de Lyon (2010) - Member of the Editorial Board of Blood (2014) - Head of the Steering Committee of the CALYM consortium

He is also a member of several professional societies, including the American Society of Hematology

Research[edit]

Salles has been especially interested in the clinical and biological study of malignant lymphoma – major focuses of his work include the description and validation of prognostic factors as well as clinical trials in indolent lymphomas. He has been involved as a coordinator or co-investigator in many clinical trials and studies within his field. Gilles Salles has led a phase I/II study[3] of rituximab, the antibody that is used most often in the treatment of lymphoma.[4]

Salles is the author of 303 publications.[5]

Video interviews[edit]

Recent publications[edit]

References[edit]

  1. ^ https://scholar.google.fr. Google Scholar https://scholar.google.fr/citations?view_op=search_authors&mauthors=gilles+salles&hl=en&oi=ao. Missing or empty |title= (help); External link in |website= (help)
  2. ^ "The teams". Fondation Synergie. Retrieved 10 June 2014. |first1= missing |last1= in Authors list (help)
  3. ^ "Obinutuzumab (GA101), a New Generation Rituximab". http://cornell-lymphoma.com. New Developments in Lymphoma. Retrieved 10 June 2014. External link in |publisher= (help)
  4. ^ "Rituximab and other antibodies in the treatment of lymphoma" (PDF). www.lymphomas.org.uk. Lymphoma Association. |first1= missing |last1= in Authors list (help)
  5. ^ Template:Pubmed, ISI-h index: 49